Results 281 to 290 of about 390,111 (338)

TRIM25 enhances hypoxia signaling by catalyzing K11-linked polyubiquitination and stabilization of HIF-α. [PDF]

J Biol Chem
Li Z, Li J, Li Z, Wang R, Yuan L, Song Y, Wang Y, Yan R, Lai F, Wang J, Xiao W.   +10 more
europepmc   +1 more source

Rapid spread of MPXV clade Ib with high genetic relatedness among men who have sex with men, Berlin, Germany, week 50 2025 up to week 10 2026. [PDF]

Euro Surveill
Bartel A, Jansen K, Boberg R, Bitzegeio J, Brinkmann A, Schrick L, Lachmann R, Sagebiel D, Nitsche A, Ruscher C, Michel J.   +10 more
europepmc   +1 more source

Evaluation of a Novel Multiplex PCR Assay for Vesicular Viruses. [PDF]

Int J Mol Sci
Sberna G, Valli MB, Colavita F, Brillo F, Rozera G, Minosse C, Maggi F, Lalle E.   +7 more
europepmc   +1 more source

Casein kinase 2-mediated phosphorylation of the splicing factor SF3B3 plays a key role in esophageal squamous cell carcinoma progression. [PDF]

PLoS Biol
Wang DC, Li JY, Wang XB, Hu GS, Nie RC, Zheng B, He YH, Liu W.   +7 more
europepmc   +1 more source

QbD Approach for Development of a Mucoadhesive Thermosensitive Gel for Oral Application: Risk Assessment Followed by Screening and Optimization. [PDF]

Gels
Dinte E, Tomuță I, Iovanov RI, Casian T, Achim AM, Ilea A, Bosca AB, Rotar H.   +7 more
europepmc   +1 more source

As Novas Diretrizes Curriculares e a Formação do Professor de Educação Física

Educação: Teoria e Prática, 2007
Larissa Cerignoni Benites, Samuel de Souza Neto   +1 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats

Journal of Ethnopharmacology, 2014
Adequate pharmacokinetic data of escin, a natural mixture of triterpene saponins used for the treatment of chronic venous insufficiency, hemorrhoids, inflammation and edema, is of special interest in view of the growing use of escin agent in clinical medicine. However, pharmacokinetic data are inadequate to support their clinical indication.
Xiu-Jun, Wu, Meng-Liang, Zhang, Xiang-Yong, Cui, J, Paul Fawcett, Jing-Kai, Gu   +4 more
openaire   +3 more sources

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

The Lancet Oncology, 2022
BACKGROUND Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC.
M. O'brien, L. Paz-Ares, S. Marréaud, U. Dafni, K. Oselin, L. Havel, E. Esteban, D. Isla, A. Martínez-Martí, M. Faehling, M. Tsuboi, Jong-Seok Lee, K. Nakagawa, Jing Yang, A. Samkari, S. Keller, M. Mauer, N. Jha, R. Stahel, B. Besse, S. Peters   +20 more
semanticscholar   +1 more source